The Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is going down by -2.57% in today’s trading session, a fall equivalent to -0.01% of the stock’s price from yesterday’s market close. A news came out on 07/23/19 stating that Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B by WSJ. The lowest point that the shares touched during the trading session was $0.22, while the peak of the day was recorded at a share price of $0.24. ATNM finished the previous session at $0.23 according to the data provided by Barchart, while the trading volume was observed to be $864,854.
In the 100 days of trading, ATNM managed to top a 0.31% Moving average. Additionally, Actinium Pharmaceuticals, Inc. shares have achieved a 52-week range between 0.20 and 0.87 alongside 100 days raw stochastic set at 4.18%.
The number of shares outstanding, according to the fundamentals of the company, is set at 157.46M, equal to the value of $35.52M in market capitalization. Financial analysts indicate that ATNM shares should be still ranked as a “Outperform”. In the last 30 days, Actinium Pharmaceuticals, Inc. shares went down by -20.73%, adding 0.27 to growth in value, on top of a +8.35% boost since 07/12/19.
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Analyst’s Estimates
Actinium Pharmaceuticals, Inc. (ATNM) could record at least -$0.04 per share in quarterly earnings in the upcoming report on 08/09/2019, a number that would actually represent an increase of 23.50% YOY.
According to the average analyst rating, Actinium Pharmaceuticals, Inc. would be rated as 2.00. Out of 2 different analysts monitoring ATNM stock, 0 analysts rate the stock as a BUY, 0 suggest to give the rating of HOLD, 2 indicate that ATNM is an OUTPERFORM, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERPERFORM.
On Dec-06-17, the stock earned a Initiated rating due to a new analyst call from B. Riley FBR, Inc., while analysts from ROTH Capital believe that the stock is set at Buy, as concluded on Oct-23-17. Maxim Group, is still rather wary about the stock, deciding to keep the rating at Buy as confirmed through a call on Sep-14-17.
Regardless of the rating, ROTH Capital did increase their price to $5 as they are considering target share price analysis. H.C. Wainwright, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on Feb-29-16, giving the stock a Buy rating.
ATNM Key Ratios To Watch:
The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at -142.38%. Beta value of the stock is recorded at 1.79. Additionally, Actinium Pharmaceuticals, Inc. is recording price volatility of 6.76% for the period of the last seven days and 7.57% in the last 30 days.
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Technical Outlook
For the period of the last 50 days, Actinium Pharmaceuticals, Inc. had its Raw Stochastic average set at 17.45% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 22.75%. Stochastic %K for Actinium Pharmaceuticals, Inc., with the last 20 days included, was set at 32.74%, having Stochastic %D topping 35.54%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be discouraging for Actinium Pharmaceuticals, Inc. stocks with recording -62.83% in metrics.
Actinium Pharmaceuticals, Inc. Insider Watch:
As far as the position of shares issued by Actinium Pharmaceuticals, Inc. (NYSE:ATNM) for the period concluded at the market close of 08/13/19, 9 institutional investors increased their positions in ATNM shares by 2,010,992, 13 decreased positions by 1,653,103 and 25 institutional investors decided to hold positions at 5,742,691. These numbers put the complete list of institutional holdings set at 9,406,786 shares, in accordance with filings submitted to the Securities and Exchange Commission. The stock had another 2 institutional investments with 43,812 new shares in addition to having 6 institutional investors selling their positions in 389,732 shares.